Designed to provide broad exposure to the Health Care ETFs category of the market, the Invesco Biotechnology & Genome ETF (PBE) is a smart beta exchange traded fund launched on 06/23/2005. What Are ...

Launched on June 23, 2005, the Invesco Biotechnology & Genome ETF (PBE) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the ...

RSPH levels the playing field across 60 established healthcare names while IBBQ bets on more than 250 biotech companies at a lower cost.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

VHT's diversified portfolio of 411 holdings delivered $1,278 from a $1,000 investment over five years, while its lower expense ratio and higher dividend yield appeal to income investors.

The iShares U.S. Healthcare ETF provides broad sector exposure with 100 holdings, while the First Trust NYSE Arca Biotechnology Index Fund focuses on a concentrated basket of 30 biotech stocks. The ...

The Invesco Pharmaceuticals ETF (NYSEMKT:PJP) offers concentrated exposure to established, profitable drugmakers with lower volatility, while the State Street SPDR S&P Biotech ETF (NYSEMKT:XBI) ...

The investment seeks is to achieve 3 times (300%) the income generated from selling options on the S&P Biotechnology Select Industry Index (the “underlying index”) by selling options on leveraged ...

Following the sale, iShares Biotechnology ETF is comprised 2.67% of DAFNA Capital’s 13F reportable assets under management. Top five holdings after the filing: NASDAQ:RVMD: $48.15 million (11.3% of ...

The investment seeks daily investment results, before fees and expenses, that correlate to two times (2x) the daily performance of the SPDR S&P Biotech ETF (the "Underlying ETF"). Under normal ...